Fortress' former asset anselamimab fails primary endpoint in Phase III CARES study

Fortress Biotech, Inc.

AstraZeneca announced anselamimab did not achieve statistical significance on primary endpoint (ACM + CVH hierarchy) in Mayo stages IIIa/IIIb AL amyloidosis.
Prespecified subgroup showed 'highly clinically meaningful improvement' in ACM and CVH; AZ plans further evaluation and regulatory discussions.
Fortress remains eligible for up to ~$125M in milestones from the 2021 Caelum sale; outcome reduces likelihood of near-term payments.
Anselamimab was well-tolerated; detailed results to be presented at future medical meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.